Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.
Preparing Adult Clinicians to Treat Pediatric Patients: Part 2
As pediatric cases of COVID-19 increase, it is vital to prepare for surges that may overwhelm capacity in pediatric intensive care units (ICUs). Pediatric critical care experts will address questions related caring for critically ill pediatric patients and steps to prepare for the next pediatric surge. We know children are not little adults. Whether you are practicing in an adult ICU environment or are a non-ICU clinician who may benefit from critical care training, this webcast will prepare you to treat critically ill pediatric patients. This webinar was held on October 15, 2021.
Coronavirus,
COVID-19,
pediatrics
Services and Supports for Longer-Term Impacts of COVID-19
The Services Report outlines federal services and mechanisms of support available to the public in addressing the longer-term effects of COVID-19. The reports represent the federal government’s response to ensure the acceleration of scientific progress and to provide individuals with Long COVID with the support and services they need. They affirm the U.S. government’s commitment to addressing the impacts of Long COVID with federal government resources, in collaboration with the private sector, and improving our Nation’s health and well-being.
COVID-19
NIH Resource: Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2. Ritonavir may also increase blood concentrations of certain concomitant medications. Because ritonavir-boosted nirmatrelvir (Paxlovid) is the only highly effective oral antiviral for the treatment of COVID-19, drug interactions that can be safely managed should not preclude the use of this medication.
Antivirals,
COVID-19
Health Worker Burnout
On May 23, United States Surgeon General Dr. Vivek Murthy issued a new advisory, the Surgeon General’s Advisory Addressing Health Worker Burnout, highlighting the urgent need to address the health worker burnout crisis across the country. This advisory details recommendations that different stakeholders can take to prevent burnout, improve health worker well-being, and strengthen the Nation’s public health infrastructure.
Well-Being,
Workforce
Fact Sheet: COVID-19 Test to Treat
Through this program, people are able to get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a health care provider, and have their prescription filled all at one location. These “One-Stop Test to Treat” sites are available at hundreds of locations nationwide, including pharmacy-based clinics, Health Resources Services Administration (HRSA)-supported federally-qualified health centers (FQHCs), and long-term care facilities. People can continue to be tested and treated by their own health care providers who
can appropriately prescribe these oral antivirals at locations where the medicines are distributed.
Antivirals,
Coronavirus,
COVID-19,
Therapies
New Paxlovid Dose Pack Authorized by FDA
On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a result, Paxlovid will soon be available in two package presentations.
COVID-19,
Pharmacology
FDA Updates Sotrovimab Emergency Use Authorization
The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022, estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider fact sheet show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time.
COVID-19,
Pharmacology
National Research Action Plan on Long COVID
The Research Plan provides the first U.S. government-wide national research agenda focused on advancing prevention, diagnosis, treatment, and provision of services and supports for individuals and families experiencing Long COVID. The reports represent the federal government’s response to ensure the acceleration of scientific progress and to provide individuals with Long COVID with the support and services they need. They affirm the U.S. government’s commitment to addressing the impacts of Long COVID with federal government resources, in collaboration with the private sector, and improving our Nation’s health and well-being.
COVID-19,
Rehabilitation Medicine
Post-ICU COVID-19 Clinics
Post-ICU COVID-19 clinics are newly established programs providing care for patients with post-intensive care syndrome (PICS) related to COVID-19. During this webcast, subject matter experts discussed how post-ICU COVID-19 clinics developed with an interdisciplinary model improve outcomes and support patients, family members, and transitions of care.
Coronavirus,
COVID-19